文献速递白血病造血干细胞移植与细胞治疗

树突状细胞疫苗作为急性髓系白血病缓解后治疗以预防或延迟复发

Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.
PubMed 文献 · Blood · 2017-08-22

这项2期研究评估了电穿孔负载WT1 mRNA的树突状细胞疫苗作为30例极高复发风险急性髓系白血病患者缓解后治疗的效果。13例患者出现可证实的抗白血病反应,9例达分子学缓解(WT1转录本水平正常化),其中5例在中位随访109.4个月后持续缓解。应答者5年总生存率高于无应答者(53.8% vs 25.0%;P = .01)。

要点

  • 13例可证实抗白血病反应,9例达分子学缓解,5例持续缓解(中位随访109.4个月)。
  • 应答者5年总生存率高于无应答者(53.8% vs 25.0%;P = .01)。
  • 首次完全缓解期接种者中,应答者5年无复发生存率高于无应答者(50% vs 7.7%;P < .0001)。

核心结论

  • 对急性髓系白血病患者接种电穿孔负载WT1 mRNA的树突状细胞疫苗,可能是预防或延迟标准化疗后复发并改善总生存率的有效策略,且与诱导WT1特异性CD8+ T细胞反应相关。

研究设计与样本

  • 2期研究,纳入30例极高复发风险的急性髓系白血病患者,以电穿孔负载Wilms瘤1(WT1)信使RNA(mRNA)的树突状细胞(DC)作为缓解后治疗。
  • 试验注册号为NCT00965224。

主要发现

  • 13例患者出现可证实的抗白血病反应。
  • 9例患者达分子学缓解(WT1转录本水平正常化),其中5例在中位随访109.4个月后持续缓解。
  • 另有4例患者达疾病稳定。
  • 应答者5年总生存率高于无应答者(53.8% vs 25.0%;P = .01)。
  • 在首次完全缓解(CR1)期接种DC的患者中,疫苗诱导的复发减少率为25%,应答者5年无复发生存率高于无应答者(50% vs 7.7%;P < .0001)。

关键数值与推荐

  • 在CR1期接种DC且年龄≤65岁和>65岁患者中,5年总生存率分别为69.2%和30.8%,而瑞典急性白血病登记处分别为51.7%和18%。
  • 长期临床反应与循环中多表位WT1特异性CD8+ T细胞频率增加相关。
  • 长期总生存率与迟发型超敏反应浸润CD8+ T淋巴细胞中干扰素-γ+和肿瘤坏死因子-α+的WT1特异性反应相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapse is a major problem in acute myeloid leukemia (AML) and adversely affects survival. In this phase 2 study, we investigated the effect of vaccination with dendritic cells (DCs) electroporated with Wilms' tumor 1 (WT1) messenger RNA (mRNA) as postremission treatment in 30 patients with AML at very high risk of relapse. There was a demonstrable antileukemic response in 13 patients. Nine patients achieved molecular remission as demonstrated by normalization of WT1 transcript levels, 5 of which were sustained after a median follow-up of 109.4 months. Disease stabilization was achieved in 4 other patients. Five-year overall survival (OS) was higher in responders than in nonresponders (53.8% vs 25.0%; P = .01). In patients receiving DCs in first complete remission (CR1), there was a vaccine-induced relapse reduction rate of 25%, and 5-year relapse-free survival was higher in responders than in nonresponders (50% vs 7.7%; P < .0001). In patients age ≤65 and >65 years who received DCs in CR1, 5-year OS was 69.2% and 30.8% respectively, as compared with 51.7% and 18% in the Swedish Acute Leukemia Registry. Long-term clinical response was correlated with increased circulating frequencies of polyepitope WT1-specific CD8+ T cells. Long-term OS was correlated with interferon-γ+ and tumor necrosis factor-α+ WT1-specific responses in delayed-type hypersensitivity-infiltrating CD8+ T lymphocytes. In conclusion, vaccination of patients with AML with WT1 mRNA-electroporated DCs can be an effective strategy to prevent or delay relapse after standard chemotherapy, translating into improved OS rates, which are correlated with the induction of WT1-specific CD8+ T-cell response. This trial was registered at www.clinicaltrials.gov as #NCT00965224.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Anguille S, Van de Velde AL, Smits EL, et al. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood. 2017. PMID: 28830889. doi:10.1182/blood-2017-04-780155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。